Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2019 | Story Leonie Bolleurs | Photo Barend Nagel
Marnus du Plooy
Marnus du Plooy, recipient of a Fulbright Scholarship, will depart for the Duke University in Durham, North Carolina, in August to complete a doctoral degree.

Marnus du Plooy will receive his master’s degree at the University of the Free State’s Winter Graduation Ceremony.

After completing his BSc degree in Microbiology, he discovered a passion for this field of research and enrolled for postgraduate studies in the Department of Microbial, Biochemical and Food Biotechnology at the UFS.

During his master’s, Du Plooy focused on the pathogenic yeasts, Cryptococcus neoformans and a related species, C. deneoformans.

Passion for science instilled at a young age

His passion for this field comes from a young age. “Both my parents were Science teachers and they instilled a love for Science in me. At school, I enjoyed the Science subjects the most and usually obtained my highest marks in these,” Du Plooy said. 

The pathogenic yeasts studied by Du Plooy, Cryptococcus neoformans and the sister species, C. deneoformans, often cause meningitis in immunocompromised individuals, such as in people living with HIV/Aids.

He pointed out: “Infection caused by these yeasts is right on the heels of TB as the second largest killer of HIV-positive patients in sub-Saharan Africa. The focus of my master’s project was to investigate new ways in which genes can be ‘switched off’ in these yeasts in order to study the role of the genes in virulence. Doing so could help to identify new drug targets for the treatment of this form of meningitis in subsequent studies.”

Expanding his international footprint

Although Du Plooy received his master’s degree from the UFS, he grabbed the opportunity to study abroad with both hands. He applied for and received a Fulbright scholarship from the Fulbright Foreign Student Programme, giving him the opportunity to study in the US.

“I did not expect to get very far with the application, as very few candidates are selected each year. I was very lucky to receive a Fulbright scholarship and an admission offer from Duke University for PhD studies in Microbiology,” said Du Plooy.

He hopes to continue with research on Cryptococcus and to contribute to improving the lives of HIV/Aids patients. “I have always been interested in pharmaceutical and medical research and noticed a need for better cryptococcal treatments, especially in sub-Saharan Africa. Cryptococcal meningitis is a neglected disease which claims more than 600 000 lives worldwide every year. The current treatment options are several decades old, with some only available in well-resourced areas.”

Du Plooy will depart for the US in August. “The duration of the degree is four to five years, where-after I will return to South Africa to apply what I have learned at home.”

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept